Authors: Zhongping Ma Jiacheng Liao Chang Zhao Daozhang Cai
Publish Date: 2015/03/07
Volume: 361, Issue: 2, Pages: 467-476
Abstract
Osteoporosis OP often increases the risk of bone fracture and other complications and is a major clinical problem Previous studies have found that high blood pressure is associated with bone formation abnormalities resulting in increased calcium loss We have investigated the effect of the antihypertensive drug benidipine on bone marrow stromal cell BMSC differentiation into osteoblasts and bone formation under osteoporotic conditions We used a combination of in vitro and in vivo approaches to test the hypothesis that benidipine promotes murine BMSC differentiation into osteoblasts Alkaline phosphatase ALP osteocalcin OCN runtrelated transcription factor 2 RUNX2 βcatenin and lowdensity lipoprotein receptorrelated protein 5 LRP5 protein expression was evaluated in primary femoral BMSCs from C57/BL6 mice cultured under osteogenic conditions for 2 weeks to examine the effects of benidipine An ovariectomized OVX mouse model was used to investigate the effect of benidipine treatment for 3 months in vivo We found that ALP OCN and RUNX2 expression was upregulated and WNT/βcatenin signaling was enhanced in vitro and in vivo In OVX mice that were intragastrically administered benidipine bone parameters trabecular thickness bone mineral density and trabecular number in the distal femoral metaphysis were significantly increased compared with control OVX mice Consistently benidipine promoted BMSC differentiation into osteoblasts and protected against bone loss in OVX mice Therefore benidipine might be a suitable candidate for the treatment of patients with postmenopausal osteoporosis and hypertensionDesign of the study ZpM JcL and DzC Acquisition of data ZpM JcL DzC and CZ Interpretation of data ZpM JcL DzC and CZ Manuscript preparation ZpM JcL DzC and CZ The authors declare no competing interests This work was not commisioned and was externally peerreviewed Ethical approval was given by the Medical Ethics Committee of Inner Mongolia Medical UniversityBD has no effect on endogenous stem cells As shown by the results of immunohistochemistry with the characteristic markers of marrow stromal cells such as CD105 a and CD106 b endogenous stem cells do not change significantly after BD treatment CD105 c and CD106 d positive cells are evenly distributed in all groups as demonstrated microscopically by immunohistochemical staining with no significant differences between each other Columns represent the means ± SD from six mice per group c d GIF 218 kb
Keywords: